Show simple item record

dc.contributor.authorPradenas, Edwards
dc.contributor.authorTrinité, Benjamin
dc.contributor.authorUrrea, Víctor
dc.contributor.authorMarfil, Silvia
dc.contributor.authorÁvila-Nieto, Carlos
dc.contributor.authorRodríguez de la Concepción, María Luisa
dc.contributor.authorTarrés-Freixas, Ferran
dc.contributor.authorPérez-Yanes, Silvia
dc.contributor.authorRovirosa, Carla
dc.contributor.authorAinsua-Enrich, Erola
dc.contributor.authorRodon, Jordi
dc.contributor.authorVergara-Alert, Júlia
dc.contributor.authorSegalés, Joaquim
dc.contributor.authorGuallar, Victor
dc.contributor.authorValencia, Alfonso
dc.contributor.authorIzquierdo-Useros, Nuria
dc.contributor.authorParedes, Roger
dc.contributor.authorMateu, Lourdes
dc.contributor.authorChamorro, Anna
dc.contributor.authorMassanella, Marta
dc.contributor.authorCarrillo, Jorge
dc.contributor.authorClotet, Bonaventura
dc.contributor.authorBlanco, Julià
dc.contributor.otherProducció Animalca
dc.date.accessioned2021-03-24T12:41:20Z
dc.date.available2021-03-24T12:41:20Z
dc.date.issued2021-01-31
dc.identifier.citationPradenas, Edwards, Benjamin Trinité, Víctor Urrea, Silvia Marfil, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, and Ferran Tarrés-Freixas et al. 2021. "Stable Neutralizing Antibody Levels 6 Months After Mild And Severe COVID-19 Episodes". Med 2 (3): 313-320.e4. doi:10.1016/j.medj.2021.01.005.ca
dc.identifier.issn2666-6340ca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/1215
dc.description.abstractBackground. Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. Methods. We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for >6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD), and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. Findings. We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted 6 months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a 2-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at 6 months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2, or NP antibody titers, all of them showing a constant decline over the follow-up period. Conclusions. Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage.ca
dc.format.extent24ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofMedca
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleStable neutralizing antibody levels 6 months after mild and severe COVID-19 episodesca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/acceptedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc619ca
dc.identifier.doihttps://doi.org/10.1016/j.medj.2021.01.005ca
dc.contributor.groupSanitat Animalca


Files in this item

 
 

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/